Drug Discovery Unit
We translate basic science into lead compounds to validate putative drug targets, to use as tools to investigate disease pathways and, when appropriate, advance to pre-clinical drug candidates.
We work to biotech style philosophy and standards incorporating, dynamic, goal driven project management based on target product profiles and compound selection criteria. Our major research themes are:
- neglected tropical diseases
- innovative targets and pathways
The DDU has all of the capabilities required for:
- early phase drug discovery
- assay development
- high throughput screening
- cell biology
- medicinal chemistry
- structural biology
- computational chemistry
- DMPK
All of these capabilities operate under one management structure to ensure an integrated approach and rapid progress.
Currently the team is about 120 people and includes substantial experience from the pharmaceutical/ biotech sector. This website contains details of current programmes and supporting infrastructure.
Head of DDU
person
Deputy Head of DDU
person
Principal Investigators
person
person
person
person
Business Development
person
Operational support
| Name | Role | |
|---|---|---|
| Lisa Robertson | Finance Business Partner | [email protected] |
| Suze Farrell | DDU Training Academy Manager | [email protected] |
| Kirstie Hughes | PA to Ian Gilbert | [email protected] |
Publications
Stories
News
A scalable gene-editing approach developed by Life Sciences researchers reveals how deadly parasites can evade promising new treatments
Press release
University of Dundee researchers have made a significant breakthrough in the global effort to combat tuberculosis.
News
END2AMR, a new Innovative Health Initiative (IHI)–funded public-private partnership bringing together academia, SMEs, and industry to accelerate innovation against antimicrobial resistance